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Abstract
The majority of traumatic brain injuries (TBIs) are categorized as mild, according to a baseline Glasgow Coma Scale (GCS)
score of 13–15. Prognostic models that were developed to predict functional outcome and persistent post-concussive
symptoms (PPCS) after mild TBI have rarely been externally validated. We aimed to externally validate models predicting
3–12-month Glasgow Outcome Scale Extended (GOSE) or PPCS in adults with mild TBI. We analyzed data from the
Collaborative European NeuroTrauma Effectiveness Research in Traumatic Brain Injury (CENTER-TBI) project, which
included 2862 adults with mild TBI, with 6-month GOSE available for 2374 and Rivermead Post-Concussion Symptoms
Questionnaire (RPQ) results available for 1605 participants. Model performance was evaluated based on calibration
(graphically and characterized by slope and intercept) and discrimination (C-index). We validated five published models for
6-month GOSE and three for 6-month PPCS scores. The models used different cutoffs for outcome and some included
symptoms measured 2 weeks post-injury. Discriminative ability varied substantially (C-index between 0.58 and 0.79). The
models developed in the Corticosteroid Randomisation After Significant Head Injury (CRASH) trial for prediction of GOSE
<5 discriminated best (C-index 0.78 and 0.79), but were poorly calibrated. The best performing models for PPCS included
2-week symptoms (C-index 0.75 and 0.76). In conclusion, none of the prognostic models for early prediction of GOSE and
PPCS has both good calibration and discrimination in persons with mild TBI. In future studies, prognostic models should be
tailored to the population with mild TBI, predicting relevant end-points based on readily available predictors.
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Traumatic brain injury (TBI) is a major health concern with>50,000,000 new cases reported globally every year.1,2 Ap-
proximately 70–90% of patients with TBI present with a Glasgow
Coma Score (GCS) of 13–15, which falls in the mild TBI category.3
Although the majority of these patients recover shortly after the
incident, a notable percentage continue to have persistent com-
plaints. These complaints can interfere with daily life and social
and work activities,4,5 and *50% of persons with mild TBI do
not return to their pre-injury level of functioning 6 months after
injury.6–8
The most prominent post-injury disturbances are cognitive,
emotional, somatic, and behavioral symptoms, often referred to as
post-concussive symptoms,9 or if the sequelae of symptoms persist
over time, post-concussion syndrome (PCS). The concept of PCS
has been questioned in recent years,10 and, therefore, some authors
refer to the multiple concurrent post-concussive symptoms several
months after TBI as persistent post-concussive/post-concussion
symptoms (PPCS).11–14 The prevalence of 6-month PPCS after
mild TBI varies substantially among studies, partly because of
differences in diagnostic criteria, and is typically between 10% and
40% in civilian samples presenting to hospitals.4,15–18
Considering the high percentage of functionally impaired per-
sons with mild TBI, the economic burden of prolonged treatment
and decreased productivity,19 it is important to promptly identify
persons who are at high risk of long-term consequences. Therefore,
a well-performing prognostic model for outcome prediction after
mild TBI is important to assist patients and health-care providers in
making well-informed treatment decisions. Before implementation
of a model for decision making in clinical practice can be consid-
ered, it is crucial to assess its performance in an external validation
study. In recent years, there have been initiatives toward external
validation of prognostic models for mild TBI,6,20 but validation
studies are still scarce. The Collaborative European NeuroTrauma
Effectiveness Research in Traumatic Brain Injury (CENTER-TBI)
project provides an excellent opportunity for external validation of
existing models in a large prospective cohort of contemporary TBI
patients from 18 countries across Europe, and Israel.21
The aim of this study was to examine the performance of existing
models for prediction of outcome following mild TBI. We searched
for published predictors and prognostic models for functional
outcome (Glasgow Outcome Scale Extended [GOSE]) and PPCS




The study population consisted of patients from the prospective
longitudinal observational CENTER-TBI study (Core data, version
2.0). Data were collected from December 2014 to December 2017
in 58 centers across Europe and Israel. Ethical approval was
granted for each recruiting site and informed consent was obtained
for all patients by the patients and/or their legal representative/next
of kin. Institutions participating in CENTER-TBI were mainly re-
ferral centers for neurotrauma. Patients who were not seen in study
hospitals were not included. Inclusion criteria for the core study
were a clinical diagnosis of TBI, presentation within 24 h after
injury, and an indication for computed tomography (CT) scanning.
The exclusion criterion was any severe pre-existing neurological
disorder that could confound outcome assessments.21 The core data
set included three strata that were differentiated according to care
path: patients seen in the emergency room (ER); patients primarily
admitted to the intensive care unit (ICU), and patients primarily
admitted to the hospital ward (non-ICU).
For this study, 2862 (‡ 16 years of age) adults with mild TBI, as
defined by a baseline GCS of 13–15, were included; 2374 of the
records had information on 6-month GOSE, and 1605 had infor-
mation on some or all 6-month Rivermead Postconcussion Symp-
toms Questionnaire (RPQ)22 items, measuring PPCS.
Measurements
Predictors. Sociodemographic, pre-injury and injury charac-
teristics were based on information in hospital charts. Imaging,
blood sampling, and neurological assessment were performed in
the ER. Post-concussive and psychological symptoms were as-
sessed at 2–3 weeks post-injury (range 10–27 days) in patients
admitted to the ER, and in some centers (participating in an addi-
tional imaging sub-study), also in patients admitted to a hospital
ward other than the ICU. The following instruments were used:
RPQ for post-concussive symptoms, PTSD Checklist for Diag-
nostic and Statistical Manual of Mental Disorders, Fifth edition
(DSM- 5) (PCL-5)23 to screen for post-traumatic stress disorder
(PTSD), Patient Health Questionnaire (PHQ -9)24 to screen for
depression, and Generalized Anxiety Disorder (GAD-7)25 to screen
for anxiety.
Outcome. The GOSE is widely used as a primary outcome
measure in TBI studies.26 The GOSE provides eight categories of
outcome: dead (1), vegetative state (2), lower severe disability (3),
upper severe disability (4), lower moderate disability (5), upper
moderate disability (6), lower good recovery (7), and upper good
recovery (8). The highest score (8) represents a complete return to a
pre-injury level of functioning.27 The GOSE was assessed 6 months
post–injury, and when outside the time window (range 5–8
months), it was imputed based on GOSE measurements at other
time points (* 30%, described in Steyerberg and coworkers).2 The
RPQ is the most frequently employed self-reported symptom in-
ventory measuring PPCS.28 The RPQ consists of 16 cognitive,
somatic, and emotional symptoms that can be assessed from
‘’not experienced at all’’ (0) to ‘’severe problem’’ (4), and it was
administered 6 months post-injury.
The self-report instruments were administered in 18 languages.
Prior to the data collection, instruments existing only in English
were translated and linguistically validated in the respective lan-
guages according to the guidelines of Acquadro.29 The linguistic
validation procedure consisted of multiple steps, including forward
translation, cognitive debriefing, backward translation, harmoni-
zation, and finalization of translated versions. A manuscript dedi-
cated to the linguistic validations is currently in preparation.
Psychometric properties of the instruments have been investigated
using criteria of the classical test and item response theory (other
publications in preparation).30–32
Selection of prognostic models
Eligible prognostic models were selected based on a rapid re-
view with pre-defined search strategy and pre-defined inclusion
criteria. Prognostic models and predictors of GOSE or PPCS were
identified by a search in MEDLINE, Embase, and the Cochrane
Library, which included studies published until May 2019
(Table S1), and reference lists of systematic reviews.33–35 Prog-
nostic models were included if they were developed to predict
GOSE or PPCS at 3–12 months post-injury in patients with GCS
13–15 at baseline. Models that were developed in populations that
included other TBI severities were also selected if at least a pro-
portion of patients had a GCS between 13 and 15. Moreover,
models had to fulfill at least one of the following quality criteria
to be considered eligible: (1) large sample size (n > 500), (2) > 10
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outcome events for each candidate predictor considered and (3) the
use of shrinkage and/or some form of internal validation.36 We
extracted predictors of outcome from eligible models and from all
studies that explored prediction of 3–12-month GOSE and PPCS in
persons with mild TBI.
Statistical analyses
The external validity of the models was assessed with measures
of calibration and discrimination. Calibration is the agreement be-
tween predicted and observed outcome values and was measured
by the calibration intercept and the calibration slope, and visual-
ized by a calibration plot. The calibration intercept expresses
calibration-in-the-large: if the outcomes are systematically under-
estimated (intercept <0) or overestimated (intercept >0), and the
calibration slope indicates if the strength of the associations be-
tween predictors and outcomes is underestimated (slope >1; ‘‘un-
derfit’’) or overestimated (slope <1; ‘‘overfit’’). A calibration plot
graphically compares mean observed with mean predicted out-
comes. In a perfect scenario, the calibration intercept and slope
would be 0 and 1, respectively, and combinations of predicted and
observed outcomes would be on the 45 degree line. Discrimination
refers to the ability to classify patients with a poor versus a good
outcome based on a prognostic model, and was assessed by the area
under the operator receiver characteristic curve (AUC), which is
equal to the concordance (C) index in logistic regression models.
The AUC or C-index ranges between 0.50 (no discrimination, equal
to chance) and 1.0 (perfect discrimination).
The C-index obtained in validation studies is influenced by
differences in both the regression coefficients (slope) and the
case-mix heterogeneity. To disentangle their influence on the dis-
criminative ability of logistical regression models, we used the
model-based concordance (mbc), which is only influenced by dif-
ferences in case-mix heterogeneity.37
All models were validated using patients with GCS 13–15
with all information on the relevant predictors available in the
CENTER-TBI data set (‘‘complete case analysis’’). When predic-
tors were not registered in CENTER- TBI, and therefore were
completely unavailable, their predictor effect was set to 0, and only
discrimination and calibration slope were assessed. As a sensitiv-
ity analysis, models were also validated in all patients with GCS
13–15, using imputation to complete missing data in predictors
(‘‘imputation analysis’’ in one complete data set).
All analyses were performed in R (3.5.3, R Foundation for
Statistical Computing, Vienna, Austria, 2019) using the rms pack-
age for model validation38 and the mice package for imputation
of missing values.39 The calibration plot was created using val
.prob.ci.2 function.40 The study was conducted and reported ac-
cording to the criteria of the Transparent Reporting of a Multi-




Based on the literature search criteria (Table S1), 417 abstracts
were screened. Based on the full-text screen, 43 articles described
predictors of 3–12-month PPCS (n = 29), GOSE (n = 11), or both
(n = 3), and 5 articles presented prognostic models for prediction
of GOSE (n = 9) and PPCS (n = 3) (Tables 1, S2, and S3). The most
frequent predictors in prognostic models were age, GCS, and
extracranial injuries, and alcohol intoxication (Table 1). Other
frequent predictors of outcome were: sex/gender,8,20,42–46 educa-
tion,6,8,20,46–51 pre-injury mental health,6,8,42,43,46,47,50,52–54 cause
of injury,6,42,45,47 neuroimaging markers,49,51,55–57 and post-injury
symptoms.8,20,54,55,58–60 (Tables 1, S4, and S5).
We validated five models predicting GOSE and three models
predicting PPCS (Tables 2 and 3). An additional three models were
deemed unsuitable for validation because >70% of predictor variables
were not available (CT and Combined Nijmegen model7) or because
the model equation was not available (emergency department
[ED] UPFRONT model8).
Eligible models predicting GOSE
Models for predicting 6-month GOSE were the Basic and CT
models from the Corticosteroid Randomisation After Significant
Head Injury (CRASH) trial;56 clinical models for mild TBI and
isolated TBI from the Nijmegen Radboud University Brain Injury
Cohort Study (RUBICS) study;57 and the ED+ model from the
UPFRONT study8 (Table 2). All models predicted dichotomized
GOSE, but with differently defined end-points: severe disability or
death (GOSE <5), disability or death (GOSE <7), or com-
plete/upper good recovery (GOSE = 8), respectively (Table 2).
They contained different predictors, but all models included a
measure of injury severity (GCS, Injury Severity Score [ISS],
or major extracranial injury), and most models also included age
and alcohol intoxication. In addition to admission characteristics,
the UPFRONT model included 2-week symptoms (Table 2), which
were assessed with different instruments than in the CENTER-TBI
study (and therefore rescaled in validation). The predictors neck
pain at the ER and coping styles from the UPFRONT model were
not assessed in the CENTER-TBI study. The CRASH models were
developed in an adult population with GCS 3–14, which partly
includes mild TBI. In our study, they were validated in adults with
GCS 13–15 and GCS 13–14. Other models were developed only in
the population with GCS 13–15. The UPFRONT model was de-
veloped in patients with loss of consciousness (LOC) <30 min and
post-traumatic amnesia (PTA) <24 h, and no major psychiatric
disorders (Table 2). These inclusion criteria were not used in our
validation, but were applicable to the majority of the validation
population and therefore were not expected to impact the results.
Eligible models predicting PPCS
Models predicting 6-month PPCS were developed in the Trans-
forming Research and Clinical Knowledge in TBI (TRACK-TBI)
pilot study, UPFRONT, and Nijmegen studies (Table 3). The end-
point was differently defined or measured by different instruments
(Table 3). In the TRACK-TBI pilot study,46 PPCS were assessed with
the RPQ and dichotomized according to International Classification
of Diseases (ICD) criteria for PCS; that is, a score ‡2 on at least three
of the following symptoms: headache, dizziness, fatigue, irritability,
sleep disturbances, poor concentration, forgetfulness, poor memory,
frustration, or depression. In the UPFRONT study, dichotomization
of PPCS was done in a similar way, but measured using the Head
Injury Severity Checklist (HISC). The Nijmegen study defined high
PPCS as a score ‡2 on 13 out of all 16 RPQ items. The TRACK-TBI
Pilot model only included admission characteristics as predictors,
whereas the other models also included symptoms measured *2
weeks post-injury (Table 3). These symptoms were assessed by
different instruments (Table S6). In addition, there were some dif-
ferences between development and validation studies in the definition
and measurement of pre-injury mental and physical health, headache,
and nausea (Table S6). The TRACK-TBI Pilot study excluded pa-
tients with major psychiatric, neurological, or life-threatening dis-
eases; UPFRONT included patients who sustained LOC or PTA, and
without substance addiction; and Nijmegen included patients age 18–
60 and LOC <30 min (Table 3). The validation population was not
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restricted based on age, psychiatric disorder, LOC, or PTA. Sub-
stance addiction and LOC >30 min were reported for only a small
number of patients in the validation population. As sensitivity ana-
lyses, the validation population for the UPFRONT model was re-
stricted to sustained LOC and/or PTA, and the validation population
for the Nijmegen model was restricted to age group 18–60 (Table S9).
CENTER-TBI data
In total, 2862 adults with mild TBI were included in CENTER-
TBI. The majority were male (64%) and approximately half were
admitted to a non-ICU hospital ward (47%). The mean age was 53
years (interquartile range [IQR] 33–68), and the mean years of
education was 13 (11–16). The majority of patients had a GCS of 15
(71%). More than a quarter had a major extracranial injury (27%)
and almost half had CT abnormalities (45%) (Table S7).
Subsamples without available 6-month outcomes did not differ
from the overall cohort in the majority of baseline characteristics,
but patients with completed 6-month RPQ were somewhat more
educated, and had more CT abnormalities at baseline, a higher
proportion of PTA and LOC, and a slightly lower percentage of
psychiatric disorders (Table S7).
Sample with both 2–3 week symptoms and 6-month outcomes
available differed from the total cohort: patients were mostly dis-
charged after ER and had a median age of 51 years (35–63), and
there was a higher proportion of females, more patients with GCS
15, and a smaller proportion of patients with major extracranial
injuries and with CT abnormalities (Table S7).
Table 1. Predictors of Glasgow Outcome Scale Extended (GOSE) and Persistent Post-Concussive Symptoms (PPCS)
from the Models Validated in the CENTER-TBI Data
Predictor
GOSE PPCS









Pre-injury and sociodemographic characteristics
Age XX XX XX XX X XX X X
Sex or gender X X X X X XX XX X
Education XX XX X X
Country income XX XX
Mental health XX XX X
Physical health X XX
Previous TBI X XX X X
Headache/migraine XX X
Seizures X
Injury and peri-injury characteristics
GCS XX XX X X XX X X
Abnormal pupillary response XX XX X X
Injury severity XX XX
Hypotension X X
Hypoxia X X
CT abnormalitiesa XX X X X X X
Cause of injury X X
Extracranial injury XX XX XX X X X
Facial fractures X
PTA X X XX XX X X
LOC X X XX X X
Time from injury X X
Alcohol intoxication XX XX XX X
Anticoagulants X X
Neck pain XX XX
Early symptomsb X XX
Post-injury symptoms at 2 weeks
Depression XX
Anxiety XX
Post-concussive symptoms XX XX XX




aHemorrhagic contusion, petechial hemorrhage, ventricle and cisterns obliteration, subarachnoid hemorrhage, mid-line shift, non-evacuated hematoma
bHeadache, nausea, dizziness
XX, final model; X, candidate predictor; CENTER-TBI, Collaborative European NeuroTrauma Effectiveness Research in Traumatic Brain Injury;
CRASH, Corticosteroid Randomisation After Significant Head Injury; CT, computed tomography; ED, emergency department; GCS, Glasgow Coma
Score; LOC, loss of consciousness; PTA, post-traumatic amnesia; RUBICS, Radboud University Brain Injury Cohort Study; TBI, traumatic brain injury;
TRACK-TBI, Transforming Research and Clinical Knowledge in TBI; UPFRONT.
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More than 70% of persons achieved good recovery (GOSE ‡7),
with 49% of persons completely returning to their pre-injury level
of functioning (GOSE = 8). Nevertheless, 11% experienced severe
disability or had died (GOSE <5) at 6 months, 43% had mild to
severe PPCS (ICD classification for PCS), and 22% had moderate
to severe PPCS (ICD classification for PCS). Distributions of some
predictors and outcomes differed in the CENTER-TBI compared
with the development studies, particularly for models from the
CRASH trial (Table S6).
Model performance in CENTER-TBI study
Models predicting GOSE. The CRASH models showed
poor calibration and good discrimination for the outcome GOSE
<5, which was observed in only 11 % of patients. Percentage of
death/unfavorable outcome was overestimated (Basic model: 20%
vs. 11%, calibration intercept = -0.82; Table 4), particularly for the
CT model (27% vs. 11%; calibration intercept = -1.38; Table 4).
In a population with GCS 13–14; that is, the patient selection
that was used in the development study, calibration-in-the-large
was better (calibration intercept = -0.26 for Basic, -1.13 for CT,
Table 4). The calibration slope was close to 1, indicating similar
effects of predictors compared with the CRASH trial. Models
showed good discriminative ability, especially the CT model
(C-index = 0.79; Table 4). The discriminative ability of the CRASH
models was somewhat reduced by the more homogeneous patient
population of CENTER-TBI compared with the development
population, as expressed by the expected C-index if the model was
correct (mbc = 0.79-80 vs. C-index of 0.81–0.83 in the development
data, Table 4).
The Nijmegen clinical models showed relatively good calibra-
tion, with slight underestimation of proportions of unfavorable
outcome (GOSE <7; 26% vs. 28%; 22% vs. 26%; Table 4). The
slopes suggested smaller effects of predictors (slope = 0.82–0.83;
Table 4) and slightly worse discriminative ability in the CENTER-
TBI than in the Nijmegen study (C-index = 0.66–0.69). The mbc
indicated a somewhat more heterogeneous patient case-mix in the
CENTER-TBI study than in the Nijmegen study (mbc = 0.72-0.70
vs. C-index 0.71–0.69; Table 4), which increased the ability to
correctly discriminate between patients with GOSE <7 and those
with GOSE ‡7.
For the ED+ model, calibration-in-the-large was not assessed
because several predictors were not registered in CENTER-TBI.
Discrimination was assessed, but it was expected to be lower be-
cause of the absence of several predictors in the CENTER-TBI
data. The ability to discriminate patients with complete recovery
(GOSE = 8) was lower than in the development study (C-index =
0.70; Table 4). Analyses of C-indices and slope suggested smaller
Table 2. Models for Predicting Glasgow Outcome Scale Extended (GOSE) Validated in the CENTER-TBI Data







Adult; GCS 3-14 GOS <4 (GOSE <5)
at 6 months





CT model Basic model plus
 Petechial hemorrhage









Clinical Adult; GCS 13-15
Neurological/surgical
consultation;

































 Depression (2 weeks)
 Anxiety (2 weeks)
 Complaints (2 weeks)
 Passive coping style




AUC, area under the curve; C, concordance; CENTER-TBI, Collaborative European NeuroTrauma Effectiveness Research in Traumatic Brain Injury;
CRASH, Corticosteroid Randomisation After Significant Head Injury; CT, computed tomography; ED, emergency department; GCS, Glasgow Coma
Score; LOC, loss of consciousness; PTA, post-traumatic amnesia; RUBICS, Radboud University Brain Injury Cohort Study; UPFRONT.
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Table 3. Models for Predicting Persistent Post-Concussive Symptoms (PPCS) Validated in the CENTER-TBI Study






3 level I trauma centers, US,
2010-2012
Score ‡2 on 3 out of 8
symptomsa (ICD)




 Years of education
 Pre-injury migraine or headache









sustained LOC or PTA, no
substance addiction,
dementia;
3 level I trauma centers, The
Netherlands, 2013-2015
















LOC <30 min, 18-60 years of
age;
1 level I trauma center, The
Netherlands, 2004-2006
Score £2 on 13 out
of 16 RPQ items at
6 months






aHeadache, dizziness, fatigue, irritability, sleep disturbances, poor concentration, forgetfulness, poor memory, frustration or depression
*After internal validation
AUC, area under the curve; CENTER-TBI, Collaborative European NeuroTrauma Effectiveness Research in Traumatic Brain Injury; GCS, Glasgow
Coma Score; HISC, Head Injury Severity Checklist; ICD, International Classification of Diseases; LOC, loss of consciousness; PTS, post-traumatic
symptoms;
RPQ, Rivermead Post-Concussion Symptoms Questionnaire; RUBICS, Radboud University Brain Injury Cohort Study; TRACK-TBI, Transforming
Research and Clinical Knowledge in TBI; UPFRONT,
Table 4. Results of External Validation of Models Predicting 6-Month Glasgow Outcome Score Extended (GOSE)
in Patients with Mild Traumatic Injury (TBI): Complete Case Analyses in the CENTER-TBI Study (n = 2269)









observed outcome mbc C (95% CI) Slope (95% CI)









0.79 0.76 [0.76, 0.77] 0.95 [0.73,1.16]









0.82 0.78 [0.73,0.84] 0.82 [0.63,1.01]
Nijmegen
Clinical













0.70 0.66 [0.59,0.74] 0.83 [0.64,1.02]
UPFRONT
ED +
0.77 548/352b / / 0.80 0.70 [0.66,0.75] 0.49 [0.36-0.62]
aSubset with Glasgow Coma Score (GCS) 13–14
bPredicting positive outcome
C, concordance; CENTER-TBI, Collaborative European NeuroTrauma Effectiveness Research in Traumatic Brain Injury; CI, confidence interval;
CRASH, Corticosteroid Randomisation After Significant Head Injury; CT, computed tomography; ED, emergency department; mbc, model based
concordance; UPFRONT.
201
effects of predictors in CENTER-TBI and substantial overfitting
(slope = 0.5; Table 4). If the regression coefficients were valid for
the CENTER-TBI sample, the model would have a good discrim-
inative ability (mbc = 0.80; Table 4), even slightly better than in the
development study (C = 0.77, Table 4) because of the more het-
erogeneous case-mix in the CENTER-TBI study.
Models predicting PPCS. The TRACK -TBI Pilot model
correctly estimated the proportion of patients with PPCS, defined
as having three or more mild to severe symptoms at 6 months (42%
vs. 42%; Table 5), but showed overfitting (slope <0.5; Table 5) and
poor discriminative ability (C-index = 0.58; Table 5). The mbc was
substantially higher than the observed C-index (mbc = 0.74 vs.
0.58, Table 5) and was equivalent to the C in the development study
(C = 0.74, Table 5). This pattern suggested that predictor effects
(regression coefficients) differed between studies, whereas case-
mix heterogeneity was comparable.
Models for prediction of PPCS, which included 2-week post-
injury symptoms were validated in a smaller sample of CENTER-
TBI patients, for whom that information was available, and they
performed well (C-index 0.75–0.76). For the UPFRONT model,
calibration-in-the-large was not assessed because of an unmeasured
predictor (neck pain) in the CENTER-TBI study. The discrimina-
tion ability (C-index = 0.75; Table 5) and the effects of predictors
were equivalent to UPFRONT (slope = 1.0; Table 5). The Nijmegen
model was well calibrated, but it slightly overestimated the pro-
portion of persons with high PPCS at 6 months (19% vs. 15%;
Table 5). The calibration slope was close to 1, indicating similar
effects of predictors. Discrimination was even slightly higher
than in the development study (C-index = 0.76; Table 5) because
of the somewhat more heterogeneous patient case-mix of the
CENTER-TBI study compared with Nijmegen.
Calibration plots are shown in a Figures S1–S7. The perfor-
mance of models was consistent in analyses after imputation of
missing values, except for models containing 2-week post-injury
symptoms, which showed lower performance (Table S8). The
sensitivity analyses with the additional inclusion criteria used in
the development study showed somewhat better performance of the
UPFRONT and Nijmegen models for PPCS (Table S9).
Discussion
This study identified predictors and prognostic models for 3–
12 month GOSE and PPCS in persons with mild TBI, and examined
the performance of five models for predicting 6-month GOSE
outcome and three models for predicting 6-month PPCS in an in-
dependent data set of mild TBI patients from the CENTER-TBI
study. Overall, the definitions of unfavorable outcome differed
among studies, and the ability of the models to distinguish between
favorable and unfavorable outcome varied substantially (C-index
0.58–0.79). The CRASH models predicting severe disability or
death discriminated best, but they were poorly calibrated to the
population of mild TBI patients. For prediction of PPCS, the
models that included 2-week post-injury symptoms showed the best
discriminative ability and were well calibrated. In models with
reasonable discriminative ability, the most frequent predictors were
age, GCS, and extracranial injuries for GOSE, and pre-injury health
and post-injury symptoms for PPCS.
CRASH models discriminated well but they largely over-
estimated the percentage of persons with poor outcome, and used
an end-point (GOSE <5) that might not be appropriate for the mild
TBI population. It was developed for mostly moderately to severely
injured patients, whereas the validation population consisted of
mildly injured patients. In the previous external validation in per-
sons with mild TBI,6 CRASH models showed good discriminative
ability and miscalibration in the population with GCS 13–14,
consistent with this study, but discriminated poorly in the total mild
TBI population. The Nijmegen model (2008) for GOSE showed
somewhat lower discriminative ability and some overfitting in our
study, and low performance in the previous external validation,6
which could be partly because of the high number of candidate
predictors and lack of internal validation in the model development.
The performance of the UPFRONT model could not completely
be assessed in the CENTER-TBI data.
The model for PPCS based on admission characteristics
(TRACK-TBI, 2008) showed poor performance, consistent with
the previous external validation.20 A relatively small sample size
for the development of the prognostic model, a particularly effec-
tive sample size for binary outcome, might have led to unstable
regression coefficients, and, consequently, differences in perfor-
mance between development and validation studies.46 In addition,
true differences in populations might also have contributed to the
differences in the effects of predictors among studies. The perfor-
mance of models containing post-injury symptoms (UPFRONT
2017, Nijmegen, 2008) were in line with their performance in the
development studies. Nevertheless, the CENTER-TBI sample in
which these models have been validated (both 2–3 week post-injury
symptoms and 6-month PCS scores available) had lower injury
severity, younger age, lower percentage of CT abnormalities,
and higher GOSE than the overall mild TBI population in the
CENTER-TBI study. Therefore, the performance of the models
may have been different in the total mild CENTER-TBI population.
Although post-injury symptoms substantially improve predic-
tion of outcomes, they are measured several days or weeks post-
Table 5. Results of External Validation of Models Predicting Persisting Post-Concussive Symptoms (PPCS)









Observed Outcome mbc C (95% CI) Slope (95% CI)
TRACK TBI Pilot;
2017
0.74 1292/544 -0.02 [-0.14,0.10] 42%; 42% 0.74 0.58 [0.55,0.61] 0.32 [0.20,0.43]
UPFRONT; 2018 0.75 408/147 / / 0.75 0.75 [0.71,0.80] 1.02 [0.78,1.27]
Nijmegen; 2008a 0.73 403/61 -0.32 [-0.62,-0.01] 19%; 15% 0.74 0.76 [0.69,0.82] 1.03 [0.77,1.28]
aTo be comparable with other models, high PCS were set as end-point instead of low PCS.
C, concordance; CENTER-TBI, Collaborative European NeuroTrauma Effectiveness Research in Traumatic Brain Injury; CI, confidence interval; ED,
emergency department; mbmc, model based concordance; TRACK-TBI, Transforming Research and Clinical Knowledge in TBI; UPFRONT.
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injury, which does not routinely happen across hospital centers and
for all persons with mild TBI. The majority of centers only follow
persons that were admitted to hospital, and frequently schedule
appointments a month or later following injury,61 when symptoms
are already persisting. The clinical applicability of a model con-
taining predictors measured after discharge is therefore debatable
for some hospital settings, and when the intention is to make pre-
dictions at the time of presentation/admission. Symptoms measured
weeks after injury may be particularly helpful for making deci-
sions about rehabilitation and specialized care. A model based on
measures of medical history, injury characteristics, and early
symptoms, which are easily obtainable and have shown associa-
tions with outcomes following TBI in previous studies, may be
more universally useful for the early prediction of outcome. For
example, protein biomarkers are currently considered to have
potential for diagnosis and prediction in the context of TBI.1,62,63
However, their prognostic value for longer-term outcomes fol-
lowing mild TBI is yet to be established.
In addition to difficulties in the selection of appropriate predic-
tors, problematic practices and lack of agreement in assessment and
definition of outcomes hinder development of prognostic models
for both GOSE and PPCS. The models for functional outcome used
different cutoffs of GOSE to define the end-point, which could
partly explain the variability in performance among them. It may
be more difficult to discriminate between persons with mild TBI
who have incomplete and those who have complete return to pre-
injury functioning (e.g., GOSE <8) than between persons with and
without disability (GOSE <7 or even GOSE <5),6 and different
predictors may be relevant for predicting upper good overall re-
covery (GOSE = 8) versus disability/death (GOSE <5). In addition,
using GOSE as an ordinal outcome seems to have added value over
dichotomization.64 It is of note that the overall utility of using
GOSE as an outcome measure in persons with mild TBI has been
disputed, because the measure may not be sensitive enough to cap-
ture different health disturbances despite good overall functioning.
Usage of a broad battery of different measures in CENTER-TBI
and TRACK-TBI studies, which cover health-related generic and
disease-specific quality of life, return to work and daily activities,
and cognitive and psychological functioning, provide new op-
portunities for prognostic modeling of outcome following mild
TBI.1,65,66 Moreover, composite measures based on several in-
struments, and encompassing different symptoms together with
global functioning, have been proposed as an alternative to
GOSE.55 Nevertheless, our study confirms that a significant per-
centage of persons with mild TBI do not return to baseline global
functioning 6 months post-injury.6,8
Similarly, there is no agreement regarding the clinical criteria
or operational definition of PCS or PPCS.17 The Common Data
Elements (CDEs) initiative, which aims to standardize data col-
lection in TBI, recommends the RPQ for assessing post-concussive
symptoms, but does not provide further guidance.67 For exam-
ple, PCS can be mapped to ICD-10 based on several RPQ
items,17,20,46,68 thereby using different scoring criteria (mild or
worse and moderate or worse symptoms); composed from all
RPQ items,58 or based on a cutoff of the total RPQ score.69
According to the classification methods and criteria in use, asso-
ciations with predictors and other outcome measures (such as
GOSE) vary substantially.17 In our study, models for PPCS used
different definitions of outcome and/or different instruments for
measuring post-concussive symptoms. Therefore, a sensible and
uniform definition of the PCS or PPCS end-point is a prerequisite
of a good model.
A limitation of this study is that some of the predictors from
validated models were not assessed in the CENTER-TBI study
(e.g., early neck pain and coping styles), which prevented assess-
ment of calibration intercepts and could have influenced other
performance indices. Moreover, some predictors and outcomes
were measured by different tools and instruments (e.g., medical
history, psychological symptoms). The differences emphasize the
importance of incorporating newly discovered predictors into the
CDEs and using uniform instruments in TBI research. Additionally,
the prognostic models we validated were selected based on our
search strategy and eligibility criteria, and do not necessarily
represent all existing prognostic models for mild TBI.
Further, a substantial percentage of CENTER-TBI patients did
not have an assessment of 2–3 week post-injury symptoms and
6-month outcomes; therefore, the models that included 2–3 week
symptoms were validated in a smaller and more favorable sub-
sample. The response rate at 6 months was, however, in line with
that in other observational studies in the field, and comparable
with the response rate in the development studies. Patients with
and without 6-month RPQ differed in some baseline characteristics,
but without a clear pattern that would suggest a substantial sys-
tematic influence on the validation results. Further, CENTER- TBI
core study included neurotrauma centers, recruitment was not
consecutive, and patients without an indication for CT were not
considered eligible. Therefore, the participants might not be rep-
resentative of mild TBI patients in other hospital and non-hospital
settings. The self-report instruments were administered in several
languages and in several European countries, but the linguistic
and cultural comparability was good (unpublished data). A major
strength of this study is the use of a large sample of contemporary
patients from different countries and numerous medical centers. In
addition, all important indices relevant for external validation
studies are reported.70
Conclusion
We assessed the performance of several prognostic models for
GOSE and PPCS. None of the models predicting GOSE have both
good discriminative ability and good calibration in persons with
mild TBI. Models for PPCS based on admission characteristics
perform poorly, whereas models that included post-injury symp-
toms perform better in terms of discrimination and calibration.
TBI-related and psychological symptoms collected at 2 weeks
improve prediction and should be collected when possible. Novel
predictors obtainable at admission, such as biomarkers, could be
incorporated in future model developments. Future studies should
improve prediction following mild TBI by developing models that
(1) distinguish well between persons who will have longer-term
negative outcomes and those who will not, (2) are calibrated to the
population of mild TBI, (3) use relevant cutoffs and end-points for
persons with mild TBI, such as return to normal life without TBI-
related symptoms, and (4) use predictors available at admission or
before discharge, which are feasible to collect in clinical practice
for early detection of persons with longer-term consequences.
These models could be extended with symptoms collected at 2–3
weeks for later stage outcome prediction.
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Maggiore Della Carità Hospital, Novara, Italy; Hugo den Boogert,
Radboud University Medical Center, Nijmegen, The Netherlands;
Bart Depreitere, University Hospitals Leuven, Leuven, Belgium;
Ðula Ðilvesi, University of Novi Sad, Novi Sad, Serbia; Abhishek
Dixit, University of Cambridge, Addenbrooke’s Hospital, Cam-
bridge, UK; Emma Donoghue, Monash University, Melbourne,
Australia; Jens Dreier, Charité – Universitätsmedizin Berlin, Ber-
lin, Germany; Guy-Loup Dulière, CHR Citadelle, Liège, Belgium;
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Fabrizio Ortolano, Fondazione IRCCS Cà Granda Ospedale Mag-
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Italy; Daniel Rueckert, Imperial College London, London, UK;
Martin Rusnák, International Neurotrauma Research Organisation,
Vienna, Austria; Juan Sahuquillo, Vall d’Hebron Research In-
stitute, Barcelona, Spain; Oliver Sakowitz, University Hospital
Heidelberg, Heidelberg, Germany and Klinik für Neurochirurgie,
Klinikum Ludwigsburg, Ludwigsburg, Germany; Renan Sanchez-
Porras, Klinik für Neurochirurgie, Klinikum Ludwigsburg,
Ludwigsburg, Germany; Janos Sandor, University of Debrecen,
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Hoedemaekers, C., Höfer, S., Horton, L., Hui, J., Huijben, J.A.,
Hutchinson, P.J., Jacobs, B., van der Jagt, M., Jankowski, S., Janssens,
K., Jelaca, B., Jones, K.M., Kamnitsas, K., Kaps, R., Karan, M.,
Katila, A., Kaukonen, K.-M., De Keyser, V., Kivisaari, R., Kolias,
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